Allscripts Healthcare Solutions Inc. has added Paul Black and Robert Cindrich to its board of directors. Black currently serves as operating executive of buyout firm Genstar Capital, and as senior advisor at New Mountain Finance Corp. Cindrich is the former senior vice president and chief legal officer for the University of Pittsburgh Medical Center.
Allscripts Healthcare Solutions, Inc. (Allscripts – NASDAQ: MDRX) today announced that its Board of Directors has appointed Paul M. Black, former Chief Operating Officer of Cerner Corporation, and The Hon. Robert J. Cindrich (Ret.), former Senior Vice President and Chief Legal Officer for the University of Pittsburgh Medical Center (UPMC), as directors, effective immediately. Mr. Black will serve on the Board’s Compensation Committee and Mr. Cindrich will serve on the Board’s Audit Committee. The Board is now set at seven directors.
“We are pleased to add two new independent directors of such a high caliber,” said Chairman Dennis Chookaszian. “Paul and Robert bring an outstanding combination of operational, governance and healthcare industry experience, which make them excellent additions to our Board. We believe their contributions and insights will be invaluable as the Company executes on its plan to deliver value for our customers, drive long-term growth and build shareholder value.”
“Allscripts has well-respected solutions, a broad and unique client base, and a compelling vision for an open, connected, community-based, individually coordinated level of care,” said Paul Black. “I’m optimistic about the market opportunity before us and looking forward to collaborating with the Board and management to execute the Company’s plan to enhance the client experience, improve healthcare outcomes and deliver value for customers, team members and shareholders.”
Robert Cindrich said, “Allscripts has an exciting opportunity to build on its leading position in the growing market for healthcare information technology. Having spent years with one of the largest and most respected integrated delivery networks in the world, I believe I can bring a unique client perspective to management and the Board. I look forward to working with my fellow directors and drawing upon my experience to help the Board and management team implement the Company’s strategic plans.”
Allscripts’ incumbent directors, including Messrs. Black and Cindrich, will stand for re-election at the Annual Meeting of Stockholders on June 15, 2012. Stockholders of record as of the close of business on April 24, 2012, will be entitled to vote. Information on all director nominees can be found in the Company’s proxy statement, which has been filed today with the Securities and Exchange Commission and will be mailed to all stockholders of record.
Paul M. Black
Mr. Black currently serves as Operating Executive of Genstar Capital, LLC, a private equity firm, and as Senior Advisor at New Mountain Finance Corporation, an investment management company. Prior to joining Genstar, Mr. Black spent over 13 years with Cerner Corporation and retired as its Chief Operating Officer in 2007 after helping build it into a $1.5 billion company. He also served as Chief Sales Officer and played an instrumental role in the company’s double digit organic growth. Prior to Cerner, Mr. Black was with IBM from 1982 to 1994 in a number of senior sales and professional services leadership positions.
Mr. Black was most recently elected to the Board of Directors of Haemonetics Corporation, a global healthcare company dedicated to providing innovative blood management solutions. He also serves on the boards of Saepio, Inc., Truman Medical Centers, and Genstar portfolio company, Netsmart Technologies. In addition, he has served as a Director with several New Mountain portfolio companies. Mr. Black received a B.S. from Iowa State University and an M.B.A. from the University of Iowa.
Robert J. Cindrich
Mr. Cindrich is the former senior vice president and chief legal officer for UPMC, a position he held from 2004 to 2010, and currently serves as senior advisor to the Office of the President of UPMC. In that role, he advises the chief executive officer, UPMC’s senior leadership, and the Board of Directors on key governance and strategic issues. Prior to UPMC, Mr. Cindrich served as a judge of the United States District Court for the Western District of Pennsylvania for 10 years. Prior to that appointment, he was active as an attorney in both government and private practice. His government practice includes serving as chair of the Pennsylvania Legislative Reapportionment Commission, 1992-93; United States District Attorney, Western Pennsylvania District, 1978-81; and Assistant District Attorney, Allegheny County, 1970-72. While in private practice, he served as defense counsel in business and commercial litigation.
Mr. Cindrich currently serves as a director of Mylan Inc., a leading generics and specialty pharmaceutical company. He is a graduate of the University of Pittsburgh School of Law and served in the United States Army Reserves and the United States Air Force Reserves.
Allscripts (NASDAQ: MDRX) delivers the insights that healthcare providers require to generate world-class outcomes. The company’s Electronic Health Record, practice management and other clinical, revenue cycle, connectivity and information solutions create a Connected Community of Health™ for physicians, hospitals and post-acute organizations. To learn more about Allscripts, please visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.
This press release contains forward-looking statements within the meaning of the federal securities laws. Statements regarding future events or developments, our future performance, as well as management’s expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements with the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, some of which are outlined below. As a result, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on our results of operations or financial condition. Such risks, uncertainties and other factors include, among other things: the possibility that the expected synergies, efficiencies and cost savings of the merger with Eclipsys Corporation (“Eclipsys”) will not be realized, or will not be realized within the expected time period; potential difficulties or delays in achieving platform and product integration and the connection and movement of data among hospitals, physicians, patients and others; the risk that the Allscripts and Eclipsys businesses will not be integrated successfully; competition within the industries in which we operate; failure to achieve certification under the Health Information Technology for Economic and Clinical Health Act could result in increased development costs, a breach of some customer obligations and could put us at a competitive disadvantage in the marketplace; the volume and timing of systems sales and installations, the length of sales cycles and the installation process and the possibility that our products will not achieve or sustain market acceptance; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; competitive pressures including product offerings, pricing and promotional activities; our ability to establish and maintain strategic relationships; undetected errors or similar problems in our software products; the outcome of any legal proceeding that has been or may be instituted against us; compliance with existing laws, regulations and industry initiatives and future changes in laws or regulations in the healthcare industry, including possible regulation of our software by the U.S. Food and Drug Administration; the possibility of product-related liabilities; our ability to attract and retain qualified personnel; the implementation and speed of acceptance of the electronic record provisions of the American Recovery and Reinvestment Act of 2009; maintaining our intellectual property rights and litigation involving intellectual property rights; risks related to third-party suppliers and our ability to obtain, use or successfully integrate third-party licensed technology; and breach of our security by third parties. See our Annual Report on Form 10-K for 2011 and other public filings with the SEC for a further discussion of these and other risks and uncertainties applicable to our business. The statements herein speak only as of their date and we undertake no duty to update any forward-looking statement whether as a result of new information, future events or changes in expectations.